Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285698 | 1.00 | KMT2A (0.39) | KMT2AL3MBTL1ALDH1A1CDC7DBF4 | |
| SCHEMBL285886 | 0.86 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1CDC7DBF4HTT | |
| SCHEMBL286096 | 0.86 | KMT2A (0.39) | KMT2AL3MBTL1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL286244 | 0.85 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2750501 | 0.82 | HCAR2 (0.38) | KMT2AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL285588 | 0.82 | KMT2A (0.41) | KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL286082 | 0.82 | KMT2A (0.41) | KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL286243 | 0.82 | KMT2A (0.41) | KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL286220 | 0.81 | GABRA5 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL285697 | 0.81 | GABRA5 (0.38) | L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |